Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regression Toward the Mean01:52

Regression Toward the Mean

6.3K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.3K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

627
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
627
Hazard Ratio01:12

Hazard Ratio

752
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
752
Randomized Experiments01:13

Randomized Experiments

6.3K
The randomization process involves assigning study participants randomly to experimental or control groups based on their probability of being equally assigned. Randomization is meant to eliminate selection bias and balance known and unknown confounding factors so that the control group is similar to the treatment group as much as possible. A computer program and a random number generator can be used to assign participants to groups in a way that minimizes bias.
Simple randomization
Simple...
6.3K
Blinding01:11

Blinding

2.9K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.9K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Envisioning an improved research strategy for detecting moderators/mediators in intervention studies: A commentary on McClure et al.

The International journal of eating disorders·2024
Same author

Letter to the Editor: Caution warranted when interpreting registry studies of medication. A response to Boland et al. (2020).

Journal of psychiatric research·2022
Same author

Is It Time to Ban the P Value?

JAMA psychiatry·2019
Same author

When meta-analyses get it wrong: response to 'treatment outcomes for anorexia nervosa: a systematic review and meta-analysis of randomized controlled trials'.

Psychological medicine·2018
Same author

"Evidence"-based medicine in eating disorders research: The problem of "confetti p values".

The International journal of eating disorders·2017
Same author

Multiple-Treatments Meta-Analysis: Are the Conclusions Supported by the Data?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2016

Related Experiment Video

Updated: Apr 28, 2026

Problem-Solving Before Instruction PS-I: A Protocol for Assessment and Intervention in Students with Different Abilities
10:26

Problem-Solving Before Instruction PS-I: A Protocol for Assessment and Intervention in Students with Different Abilities

Published on: September 11, 2021

3.1K

A mediator effect size in randomized clinical trials.

Helena Chmura Kraemer1

  • 1Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.

International Journal of Methods in Psychiatric Research
|June 20, 2014
PubMed
Summary

This study introduces a new mediator effect size index to quantify the clinical importance of mediators in randomized clinical trials. This index helps understand how treatments achieve outcomes and improve their effectiveness.

Keywords:
effect sizesmediatorsrandomized clinical trials

More Related Videos

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.4K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

2.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Problem-Solving Before Instruction PS-I: A Protocol for Assessment and Intervention in Students with Different Abilities
10:26

Problem-Solving Before Instruction PS-I: A Protocol for Assessment and Intervention in Students with Different Abilities

Published on: September 11, 2021

3.1K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

1.4K
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
08:33

Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research

Published on: January 5, 2024

2.0K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Causal Inference

Background:

  • Understanding treatment mechanisms requires identifying mediators linking treatments to outcomes.
  • Quantifying the clinical importance of mediators is crucial for improving treatment efficacy in randomized clinical trials (RCTs).

Purpose of the Study:

  • To develop a novel mediator effect size index for interpreting the clinical significance of mediators in RCTs.
  • To provide a method for assessing the causal impact of mediators on treatment outcomes.

Main Methods:

  • Derived a mediator effect size for linear models and generalized it for categorical mediators.
  • Ensured the index is invariant to rescaling of mediator and outcome variables.
  • Defined the index based on the difference between observed and maximal potential treatment effects.

Main Results:

  • Introduced a new mediator effect size index applicable to various mediator types (categorical, ordered/non-ordered).
  • The proposed index facilitates the interpretation of mediator's clinical importance in RCTs.
  • Addressed complexities including multiple treatments, outcomes, mediators, and causal inference.

Conclusions:

  • The developed mediator effect size index offers a valuable tool for causal inference in clinical trials.
  • This approach enhances the understanding of treatment pathways and aids in optimizing treatment strategies.
  • The study provides practical illustrations for applying the new index in real-world research.